Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy targets unresectable liver cancer

NCT ID NCT07281664

First seen Jan 05, 2026 · Last updated Jun 17, 2026 · Updated 23 times

Summary

This study tests a new combination treatment for people with advanced liver cancer that cannot be surgically removed. The treatment includes a procedure that delivers chemotherapy directly to the tumor (TACE) plus two drugs that boost the immune system and block blood vessel growth. The goal is to see if this approach can shrink tumors and help patients live longer, while monitoring side effects. About 30 adults aged 18 to 75 with good liver function and no prior systemic therapy will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.